A company insider recently sold 100,000 shares of Edgewise Therapeutics Inc [EWTX]. Should You also Consider to Sale?

Edgewise Therapeutics Inc’s recently made public that its Chief Scientific Officer Russell Alan J unloaded Company’s shares for reported $1.46 million on Aug 26 ’25. In the deal valued at $14.60 per share,100,000 shares were sold. As a result of this transaction, Russell Alan J now holds 23,400 shares worth roughly $0.34 million.

Then, ALAN J RUSSELL bought 100,000 shares, generating $1,459,760 in total proceeds.

Before that, MOORE JOHN R sold 2,098 shares. Edgewise Therapeutics Inc shares valued at $28,097 were divested by the General Counsel at a price of $13.39 per share. As a result of the transaction, MOORE JOHN R now holds 10,214 shares, worth roughly $0.15 million.

Raymond James initiated its Edgewise Therapeutics Inc [EWTX] rating to a Strong buy in a research note published on July 30, 2025; the price target was $46. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Guggenheim began covering EWTX with “Buy” recommendation on April 30, 2025. Scotiabank revised its rating on April 02, 2025. It rated EWTX as “a Sector perform” which previously was an “a Sector outperform”.

Price Performance Review of EWTX

On Friday, Edgewise Therapeutics Inc [NASDAQ:EWTX] saw its stock fall -2.05% to $14.35. Over the last five days, the stock has lost -3.37%. Edgewise Therapeutics Inc shares have fallen nearly -27.45% since the year began. Nevertheless, the stocks have fallen -46.25% over the past one year. While a 52-week high of $38.12 was reached on 02/06/25, a 52-week low of $10.60 was recorded on 04/07/25.

Levels Of Support And Resistance For EWTX Stock

The 24-hour chart illustrates a support level at 14.08, which if violated will result in even more drops to 13.81. On the upside, there is a resistance level at 14.66. A further resistance level may holdings at 14.97.

How much short interest is there in Edgewise Therapeutics Inc?

A steep rise in short interest was recorded in Edgewise Therapeutics Inc stocks on 2025-08-15, dropping by -0.86 million shares to a total of 10.22 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 11.07 million shares. There was a decline of -8.41%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on March 07, 2025 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $50 price target.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.